Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318235 | 0.94 | KDM4E (0.71) | KDM4EALDH1A1GAAPOLBKMT2A | |
| SCHEMBL22420546 | 0.92 | MAOB (0.72) | KDM4EALDH1A1POLBMAOBKMT2A | |
| SCHEMBL3319335 | 0.88 | KDM4E (0.70) | KDM4EALDH1A1GAAPOLBKMT2A | |
| SCHEMBL3314287 | 0.87 | KDM4E (0.74) | KDM4EALDH1A1POLBMAOBKMT2A | |
| SCHEMBL3314542 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL3314425 | 0.86 | KDM4E (0.70) | KDM4EALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL3310748 | 0.86 | KDM4E (0.70) | KDM4EALDH1A1POLBKMT2A | |
| SCHEMBL10074852 | 0.85 | POLB (0.68) | KDM4EALDH1A1POLBMAOBKMT2A | |
| SCHEMBL31574569 | 0.85 | POLB (0.68) | KDM4EALDH1A1POLBMAOBKMT2A | |
| SCHEMBL3314726 | 0.85 | KDM4E (0.69) | KDM4EALDH1A1POLBMAOBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774063-B2 | Materials and method for inhibiting replication protein A and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774063-B2 | Materials and method for inhibiting replication protein A and uses thereof | RPA1, RPA3, PCNA | KDM4E 3143/4885ALDH1A1 4315/4885GAA 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.